Alvotech Resolved European Patent Dispute with AbbVie for AVT02 (biosimilar, adalimumab)
Shots:
- Alvotech has resolved the disputes with AbbVie in the EU & selected markets outside of the EU related to AVT02 biosimilar. & has received a non-exclusive, royalty-bearing license to AbbVie’s IP relating to Humira
- Alvotech’s exclusive partner STADA will commercialize AVT02, a citrate-free, high-concentration (100 mg/mL) biosimilar to Humira in EU countries under the brand name Hukyndra & plans to launch it in the EU for inflammatory conditions inc. RA, PsO & CD
- The US FDA has accepted the BLA’s review for ATV02 in Feb 2022 based on a switching study that demonstrated bioequivalence, comparable efficacy, safety & immunogenicity switches of Humira vs AVT02
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
